Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fredrik Y Frejd

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Experimental & Molecular Medicine|March 25, 2017
Affibody molecules as engineered protein drugsFredrik Y Frejd, Kyu-Tae Kim
Current Opinion in Biotechnology|July 6, 2011
Non-immunoglobulin based protein scaffoldsJohn Löfblom, Fredrik Y Frejd, Stefan Ståhl
EJNMMI Radiopharmacy and Chemistry|June 25, 2020
Imaging using radiolabelled targeted proteins: radioimmunodetection and beyondJavad Garousi, Anna Orlova, Fredrik Y Frejd, et al.
Mabs|August 18, 2016
Targeting HER3 using mono- and bispecific antibodies or alternative scaffoldsMagdalena Malm, Fredrik Y Frejd, Stefan Ståhl, et al.
International Journal of Oncology|June 6, 2015
Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domainHao Liu, Johan Seijsing, Fredrik Y Frejd, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 11, 2008
Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody moleculesVladimir Tolmachev, Eskender Mume, Stefan Sjöberg, et al.
Biotechnology and Applied Biochemistry|June 24, 2009
Generation of tumour-necrosis-factor-alpha-specific affibody molecules capable of blocking receptor binding in vitroAndreas Jonsson, Helena Wållberg, Nina Herne, et al.
Bioconjugate Chemistry|May 14, 2009
Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL)Julia Beuttler, Miriam Rothdiener, Dafne Müller, et al.
Scientific Reports|March 25, 2018
In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptorJohan Seijsing, Shengze Yu, Fredrik Y Frejd, et al.
Physics in Medicine and Biology|December 4, 2025
Evaluation of CD44v6-targeted radionuclide therapy on bone marrow, skin and esophageal epithelium using a novel internal dosimetry modelJens Hemmingsson, Marika Nestor, Anja Lundgren Mortensen, et al.
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Experimental & Molecular Medicine|March 25, 2017
Affibody molecules as engineered protein drugsFredrik Y Frejd, Kyu-Tae Kim
Current Opinion in Biotechnology|July 6, 2011
Non-immunoglobulin based protein scaffoldsJohn Löfblom, Fredrik Y Frejd, Stefan Ståhl
EJNMMI Radiopharmacy and Chemistry|June 25, 2020
Imaging using radiolabelled targeted proteins: radioimmunodetection and beyondJavad Garousi, Anna Orlova, Fredrik Y Frejd, et al.
Mabs|August 18, 2016
Targeting HER3 using mono- and bispecific antibodies or alternative scaffoldsMagdalena Malm, Fredrik Y Frejd, Stefan Ståhl, et al.
International Journal of Oncology|June 6, 2015
Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domainHao Liu, Johan Seijsing, Fredrik Y Frejd, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 11, 2008
Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody moleculesVladimir Tolmachev, Eskender Mume, Stefan Sjöberg, et al.
Biotechnology and Applied Biochemistry|June 24, 2009
Generation of tumour-necrosis-factor-alpha-specific affibody molecules capable of blocking receptor binding in vitroAndreas Jonsson, Helena Wållberg, Nina Herne, et al.
Bioconjugate Chemistry|May 14, 2009
Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL)Julia Beuttler, Miriam Rothdiener, Dafne Müller, et al.
Scientific Reports|March 25, 2018
In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptorJohan Seijsing, Shengze Yu, Fredrik Y Frejd, et al.
Physics in Medicine and Biology|December 4, 2025
Evaluation of CD44v6-targeted radionuclide therapy on bone marrow, skin and esophageal epithelium using a novel internal dosimetry modelJens Hemmingsson, Marika Nestor, Anja Lundgren Mortensen, et al.
Pageof 8